ALK and neoplasm: Thus, the combination of BET inhibitors and ALKi may have a relevant impact not only in the treatment of naïve ALCL but importantly also in patients with ALK+ solid tumors (who frequently display resistant mutated phenotypes [9]) or with a neoplasm counteracting ALK inhibition via alternative bypass mechanisms [47].